CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings (Accumulated Deficit) Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2022				20,000,000	20,000,000
Beginning balance at Dec. 31, 2022	$ 10,023	$ (220)	$ 9,803	$ 2	$ 2	$ 0	$ 0	$ 11,928	$ (220)	$ 11,708	$ (1,907)	$ (1,907)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	(46)										(46)
Net (loss) income	483							483
Ending balance (in shares) at Jun. 30, 2023				20,000,000
Ending balance at Jun. 30, 2023	10,240			$ 2		0		12,191			(1,953)
Beginning balance (in shares) at Mar. 31, 2023				20,000,000
Beginning balance at Mar. 31, 2023	10,705			$ 2		0		12,522			(1,819)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	(134)										(134)
Net (loss) income	(331)							(331)
Ending balance (in shares) at Jun. 30, 2023				20,000,000
Ending balance at Jun. 30, 2023	$ 10,240			$ 2		0		12,191			(1,953)
Beginning balance (in shares) at Dec. 31, 2023	20,000,000			20,000,000
Beginning balance at Dec. 31, 2023	$ 9,402			$ 2		0		11,392			(1,992)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with initial public offering, net of underwriting fees and commissions and net of deferred transaction costs of $3,298 (in shares)				6,000,000
Issuance of common stock in connection with initial public offering, net of underwriting fees and commissions and net of deferred transaction costs of $3,298	102,722			$ 1		102,721
Conversion of Micron Note into common stock (in shares)				294,217
Conversion of Micron Note into common stock	5,589					5,589
Stock-based compensation expense	21,527					21,527
Other comprehensive income (loss)	(384)										(384)
Net (loss) income	$ (37,010)							(37,010)
Ending balance (in shares) at Jun. 30, 2024	26,294,217			26,294,217
Ending balance at Jun. 30, 2024	$ 101,846			$ 3		129,837		(25,618)			(2,376)
Beginning balance (in shares) at Mar. 31, 2024				20,000,000
Beginning balance at Mar. 31, 2024	10,595			$ 2		0		12,770			(2,177)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with initial public offering, net of underwriting fees and commissions and net of deferred transaction costs of $3,298 (in shares)				6,000,000
Issuance of common stock in connection with initial public offering, net of underwriting fees and commissions and net of deferred transaction costs of $3,298	102,722			$ 1		102,721
Conversion of Micron Note into common stock (in shares)				294,217
Conversion of Micron Note into common stock	5,589					5,589
Stock-based compensation expense	21,527					21,527
Other comprehensive income (loss)	(199)										(199)
Net (loss) income	$ (38,388)							(38,388)
Ending balance (in shares) at Jun. 30, 2024	26,294,217			26,294,217
Ending balance at Jun. 30, 2024	$ 101,846			$ 3		$ 129,837		$ (25,618)			$ (2,376)